Edesa Biotech announces $3.5M PIPE led by CEO; funds vitiligo program

Edesa Biotech, Inc.

Gross proceeds ~$3.5M from sale of 729,241 common shares to healthcare-focused investors and CEO.
Investors pay $4.69/share; CEO pays $5.21/share; closing expected June 15, 2026.
Net proceeds to fund advancement of vitiligo program and drug candidate paridiprubart, plus working capital.
Company entered Registration Rights Agreement to file resale registration statement within 45 days of closing.
Securities offered under Section 4(a)(2) and Regulation D; no underwriter or placement agent used.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Edesa Biotech, Inc. issued an aggregate of 729,241 common shares of common stock to certain investors for aggregate purchase price of approximately $3.5 million.

Security: common stock
Shares: an aggregate of 729,241 common shares
Purchaser: certain investors
Consideration: aggregate purchase price of approximately $3.5 million

Exact text from the filing

Pursuant to the Purchase Agreement, the Purchasers have agreed to purchase, for an aggregate purchase price of approximately $3.5 million, an aggregate of 729,241 common shares (“Shares”), without par value, at a purchase price of $4.69 per Share for Purchasers other than the Company’s Chief Executive Officer, and $5.21 per Share for the Company’s Chief Executive Officer.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Edesa Biotech, Inc. entered into Securities Purchase Agreement with certain investors (each, a Purchaser and collectively, the Purchasers) valued at $3.5 million aggregate purchase price for 729,241 common shares at $4.69 per Share ($5.21 per Share (effective 2026-06-10).

Action: entry
Agreement: equity purchase
Counterparty: certain investors (each, a Purchaser and collectively, the Purchasers)
Value: $3.5 million aggregate purchase price for 729,241 common shares at $4.69 per Share ($5.21 per Share
Effective: 2026-06-10

Exact text from the filing

On June 10, 2026, Edesa Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain investors (each, a “Purchaser” and collectively, the “Purchasers”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Edesa Biotech, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company agrees to file registration statement for resale of shares within 45 days after Closing (effective 2026-06-10).

Action: entry
Counterparty: the Purchasers
Value: Company agrees to file registration statement for resale of shares within 45 days after Closing
Effective: 2026-06-10

Exact text from the filing

Also on June 10, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers.

View on SEC.gov

226 equity issuances filed in the last 30 days. Browse all equity issuances →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-004053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.